Moreover, SF3B1 mutations also occur frequently in non-myeloid neoplasms such as chronic lymphocytic leukemia/small lymphocytic lymphoma, and have been associated with resistance to fludarabine therapy and poor clinical outcomes [18]. This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.